5NX.F NEXSTIM OYJ
- Market cap
- EUR 62.7M
- P/E
- -
- P/B
- 7.32x
- ROE
- 13.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 5NX.F undervalued?
Graham numberThe Graham number of NEXSTIM OYJ cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NEXSTIM OYJ fundamental analysis
No fundamental analysis for NEXSTIM OYJ yet.
NEXSTIM OYJ stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NEXSTIM OYJ
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilate…
Full company profileNEXSTIM OYJ financial statements
NEXSTIM OYJ annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 6.40M | 9.53M | 7.25M | 8.74M | 11.0M |
| Gross Profit | 6.22M | 9.52M | 6.98M | 8.38M | 9.90M |
| Operating Income | -1.45M | 840K | -1.19M | -535K | 636K |
| EBITDA | - | 1.86M | -511K | 456K | 1.83M |
| Net Income | -832K | 1.31M | -1.33M | -892K | 573K |
| EPS | -0.12 | 0.19 | -0.20 | -0.12 | 0.08 |
| Balance Sheet | |||||
| Total Assets | 10.0M | 10.2M | 9.88M | 14.2M | 13.2M |
| Total Liabilities | 6.84M | 6.15M | 7.05M | 10.5M | 8.98M |
| Shareholders' Equity | 3.20M | 4.07M | 2.84M | 3.70M | 4.18M |
| Cash & Short-term Investments | 5.19M | 4.44M | 1.45M | 3.86M | 2.68M |
| Cash Flow | |||||
| Operating Cash Flow | -2.11M | 1.00M | -2.27M | 1.88M | 1.67M |
| Capital Expenditure | 1.61M | 1.44M | 1.49M | 1.71M | 1.70M |
| Free Cash Flow | -3.72M | -438K | -3.76M | 175K | -37.3K |
| Ratios | |||||
| ROE | -26.0% | 32.1% | -46.8% | -24.1% | 13.7% |
| ROA | -8.3% | 12.8% | -13.4% | -6.3% | 4.4% |
| Net Profit Margin | -13.0% | 13.7% | -18.3% | -10.2% | 5.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NEXSTIM OYJ dividends
NEXSTIM OYJ has not paid dividends in the last 5 fiscal years.
Last stock split: 1:100 on May 17, 2021.
Who owns NEXSTIM OYJ
- Insiders 39.26%
- Institutions 8.74%
- Public & others 52.01%
- Shares outstanding 7.23M
- Free float 4.74M
NEXSTIM OYJ company profile
- Company name
- NEXSTIM OYJ
- Ticker
- 5NX.F
- ISIN
- FI4000506811
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 44
- Fiscal year end
- December
- Address
- Elimäenkatu 9 B, Helsinki, Finland, 00510
- Phone
- 358 9272 7170
- Website
- nexstim.com
About NEXSTIM OYJ
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.
NEXSTIM OYJ management
3- Mr. Mikko KarvinenChief Executive Officer · born 1976
- Mr. Joonas JuokslahtiChief Financial Officer · born 1986
- Mr. Henri HannulaChief Commercial Officer · born 1974